China's proposed annual NRDL revisions could increase pricing pressure

China's proposed guidelines regarding the annual revision of its National Drug Reimbursement List could increase pricing pressure for all included drugs.

Draft opinions released by China’s National Healthcare Security Administration (NHSA) Wednesday proposed extending price negotiations, adjustments or centralized procurement to all drugs on or seeking inclusion on the NRDL. The payment standards for some drugs, including psychotropic substances, will be determined by the government. ...